Search Results
Your search for The A,The A matches 32372 pages
Showing 27601 - 27650AACR CEO Discusses the Global Status of Cancer at Seminar in Turin, Italy
Margaret Foti, PhD, MD (hc), Chief Executive Officer of the American Association for Cancer Research (AACR), recently spoke at the Institute for Cancer Research and Treatment (IRCC) in Turin, Italy, on November 25. Her lecture was titled “Reflections on the Global Cancer Research Landscape.” The...
Antacids Linked to Better Survival in Patients With Head and Neck Cancer
Patients with head and neck cancer who used antacid medicines to control acid reflux had better overall survival, according to a study from the University of Michigan Comprehensive Cancer Center. Results of the study were published in Cancer Prevention Research.1 Reflux can be a common side effect...
Karmanos Cancer Institute’s Hayley Thompson, PhD, Awarded $1.8 Million Grant to Improve Access to Cancer Survivor Resources
Hayley S. Thompson, PhD, Associate Professor, Population Studies and Disparities Research Program at the Barbara Ann Karmanos Cancer Institute, and Department of Oncology, Wayne State University School of Medicine, was recently awarded a $1.8 million grant from the Agency for Healthcare Research...
Dr. Matthew J. Ellis Named Director of Lester and Sue Smith Breast Center
Matthew J. Ellis, MD, PhD, a renowned clinician scientist in the area of genomics and molecular profiling of breast cancer, was named the new Director of the Lester and Sue Smith Breast Center at Baylor College of Medicine. Dr. Ellis assumed his new role in September 2014, succeeding C. Kent...
Ixazomib Receives Breakthrough Therapy Designation for Relapsed or Refractory Systemic Light-Chain Amyloidosis
The U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy status to Takeda Pharmaceuticals’ investigational, oral proteasome inhibitor, ixazomib (MLN9708), for the treatment of relapsed or refractory systemic light-chain amyloidosis. This is the first proteasome inhibitor and...
Center to Advance Palliative Care
In the first quarter of 2015, the Center to Advance Palliative Care (CAPC) will become a member-based organization. Member organizations will have unlimited access to CAPC tools, training, and hands-on technical assistance. At that time, CAPC will launch the first of its online curricula, broken...
Palliative Care in 2014
Palliative care expert Diane E. Meier, MD, is the Director of the Center to Advance Palliative Care (CAPC), a national organization devoted to enhancing the number and quality of palliative care programs across the nation. Under her leadership, the number of palliative care programs in the United...
RSNA Awards Gold Medal to Three Leaders in Radiology
The Radiological Society of North America (RSNA) awarded the Gold Medal, the organization’s highest honor, to three individuals at the RSNA 100th Scientific Assembly and Annual Meeting: Gary J. Becker, MD, of Tucson; Allen S. Lichter, MD, FASCO, of Alexandria, Virginia; and Etta D. Pisano, MD, of...
FDA Guidance on the Use of Pathologic Complete Response in Development of New Treatments for High-Risk Early Breast Cancer Includes ASCO Suggestions
The U.S. Food and Drug Administration’s (FDA) final Guidance for Industry on Pathologic Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer incorporates two changes that ASCO had proposed in comments submitted to the agency on a draft guidance issued in 2012. The...
Don’t Forget: Make Your Year-End Gift to the Conquer Cancer Foundation
The end of the year is often a busy time, filled with family, friends, and holiday celebrations. For many, it is also a time to embrace the spirit of giving and make annual donations to favorite charities. The Conquer Cancer Foundation leverages the expertise and passion of ASCO’s members to...
Cancer Care Incomplete Without Palliative Care Integration
ASCO recognizes that an array of efforts are needed to fully integrate palliative care into the cancer care continuum, and the Society is committed to facilitating the integration of palliative cancer care into existing health-care systems worldwide in order to realize the vision of comprehensive...
Looking to the Future: ASCO’s 50th Anniversary Year Comes to a Close
Fifty years ago, a group of seven cancer physicians banded together with a single purpose: to improve the care of people with cancer. At the time, cancer was viewed as a monolithic and frequently incurable disease, with only a handful of hard-to-tolerate and mostly ineffective therapies available....
Conquer Cancer Foundation and Michael’s Mission Work Together to Conquer Colorectal Cancer
"Nobody tells a 28 year old to get a colonoscopy.” It’s the sad but true reality that many young adults may be at risk for colorectal cancer. Unfortunately, many people, young adults in particular, are not aware of the risk factors and do not get screened early enough to catch the disease when it...
Policy Issues in Molecularly Targeted Therapy: The Science, the Money, the Applications
In the past decade, much new knowledge about the molecular underpinnings of cancer has accumulated, and the array of molecular aberrations in each individual tumor can be assessed through genomic sequencing and other tests. The rationale for and feasibility of developing molecularly targeted...
Immune-Suppressing Protein in Noncancerous Cells of Cancer Patients Offers Clue to Drug Response
A multicenter phase I study using an investigational immune therapy drug has found that the presence of the immune-suppressing protein PD-L1 in noncancerous immune cells can predict how patients with different types of advanced cancer will respond to treatment. The study, led by a Yale Cancer...
Benefits of Exercise for Relieving Fatigue in Cancer Survivors
Fatigue is such a common—and ongoing—problem among cancer survivors, last spring, ASCO published a clinical practice guideline1 to address screening, assessment, and treatment approaches for the management of fatigue after patients have completed treatment. Among the strategies included in the...
Racing Against Acute Lymphoblastic Leukemia: CTL019 Is a Fast CAR With Sustained Endurance
The long-term outcome for patients with relapsed or refractory acute lymphoblastic leukemia (ALL) is poor, with 5-year overall survival from first relapse being only approximately 10%.1,2 Patients with disease relapse following allogeneic transplant have the worse prognosis and are typically...
Getting the Most Out of Ipilimumab in Melanoma
Ipilimumab (Yervoy) was first approved by the U.S. Food and Drug Administration (FDA) in 2011 on the basis of an improvement in overall survival compared with gp100 vaccine in patients with advanced melanoma.1 Response rates with ipilimumab have been modest at best—10% to 15% using 3 mg/kg and 15%...
Phase II Study Shows Improved Survival With Addition of Sargramostim to Ipilimumab in Metastatic Melanoma
Use of the granulocyte-macrophage colony-stimulating factor (GM-CSF) sargramostim (Leukine) together with the cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) inhibitor ipilimumab (Yervoy) prolonged overall survival but not progression-free survival in patients with metastatic melanoma,...
Moving a Mountain: Crizotinib in ROS1-Rearranged NSCLC
It was thousands of years ago in China. An elderly man was unhappy with the mountain that embraced his seaside village. He would need to walk for hours before he could reach the nearest town. So, as the old fable goes, he set his mind to move the mountain. Every day, he dug up basketfuls of rocks...
Crizotinib Is Highly Active in ROS1-Rearranged NSCLC
Crizotinib (Xalkori) produced a high response rate and durable responses in patients with ROS1-rearranged non–small cell lung cancer (NSCLC), according to a study reported in The New England Journal of Medicine.1 Lead authors Alice T. Shaw, MD, PhD, of Massachusetts General Hospital Cancer Center,...
Marlo Thomas Receives Presidential Medal of Freedom
On November 24, 2014, St. Jude Children’s Research Hospital® National Outreach Director, Marlo Thomas, was presented with the Presidential Medal of Freedom, the nation’s highest civilian honor, during a special ceremony at the White House. With Ms. Thomas as its envoy to millions of supporters, St. ...
ASCO Expert Statement on Cancer Survivorship Care Planning: Timing Is Everything
As the saying goes, “Timing is everything.” And so it is with the recently released ASCO Clinical Expert Statement on survivorship care planning.1 Although there has been extensive discussion and debate about the use of survivorship care plans since the publication of the 2005 Institute of Medicine ...
ASCO Clinical Expert Statement on Cancer Survivorship Care Planning
Efforts at implementing survivorship care plans have met with limited success in oncology practice, in part due to the time required to complete them, the lack of role clarity, and the lack of reimbursement for time to complete the documents. In response, ASCO convened a Survivorship Care Planning...
Expert Point of View: Justin Gainor, MD
This is a very exciting time in lung cancer. Immunotherapy is extremely promising,” stated Justin Gainor, MD, a thoracic oncologist at Massachusetts General Hospital in Boston. The promise of immunotherapy extends to a broad patient population. Targeted treatments have transformed the lives of...
Lung Cancer: Next Frontier for Immunotherapy
Immune checkpoint inhibitors, particularly PD-1 (programmed cell death-1) and PD-L1 (programmed death-ligand 1) inhibitors, are being studied extensively in lung cancer. These agents, alone and in combination, appear to have the potential to change the management of non–small cell lung cancer...
Choice for Metastatic Pancreatic Cancer: FOLFIRINOX or Gemcitabine/Nab-Paclitaxel?
The choice between FOLFIRINOX (fluorouracil [5-FU], leucovorin, irinotecan, oxaliplatin) vs the combination of gemcitabine and nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) for first-line treatment of metastatic pancreatic cancer is not much of a contest, judging by a discussion of...
New Serologic Assay May Help Predict Recurrences in Merkel Cell Carcinoma
A new and inexpensive serologic assay may help to predict recurrences of Merkel cell carcinoma, according to Paul Nghiem, MD, PhD, the Michael Piepkorn Endowed Chair in Dermatology Research at the University of Washington, Seattle, who helped develop the test.1 Dr. Nghiem and other experts in...
Hedgehog Inhibitors Can Be Life-Altering in Patients With Advanced Basal Cell Carcinoma
What advanced basal cell carcinomas lack in frequency, they make up for in morbidity, and for these challenging patients, the hedgehog inhibitors have changed lives, according to experts at the 3rd Annual World Cutaneous Malignancies Congress, held recently in San Francisco. “The majority of basal...
3D Mammography Improves Cancer Detection in Dense Breasts
A study presented at the annual meeting of the Radiological Society of North America (RSNA 2014) has found that digital breast tomosynthesis, also known as three-dimensional (3D) mammography, has the potential to significantly increase the cancer detection rate in mammography screening of women...
Breast Cancer Research Foundation Commits Record $58.6 Million in Research Grants
The Breast Cancer Research Foundation (BCRF) announced its dedication of $58.6 million to breast cancer research at its annual Symposium & Awards Luncheon. Totaling $47 million, the 2014–2015 annual grants, awarded to more than 220 physicians and scientists on six continents, continue to fuel...
Expert Point of View: Ethan Basch, MD
Formal discussant of the patient-reported outcomes study by Smith et al presented at the Quality Care Symposium in Boston, Ethan Basch, MD, Director of the Cancer Outcomes Research Program at the University of North Carolina School of Medicine in Chapel Hill, praised the research for its important...
Study Reveals Gaps in Symptom Management
The Patient-Reported Outcomes Symptoms and Side-Effects Study demonstrated that many cancer patients treated in community cancer centers are not discussing their common symptoms like pain, fatigue, and emotional distress with their oncologists/health-care team or receiving advice about how to...
Expert Point of View: Deborah Schrag, MD, MPH
Formal discussant of this abstract, Deborah Schrag, MD, MPH, Dana-Farber Cancer Institute, praised this effort. “Dr. Stuver’s abstract provides ample evidence of overuse of intensive care at the end of life. Patients and their families do not want to be in the hospital or emergency department at...
Private Payer and Academic Center Data Capture Inappropriate Use of End-of-Life Care
Data sharing between a comprehensive cancer center and a private insurer appears to be a novel way to capture practice patterns that can point to potential quality improvements. A study that combined data from Dana-Farber Cancer Institute and Blue Cross Blue Shield of Massachusetts showed that some ...
Revisiting Successes in Advanced NSCLC to Test Value in Earlier-Stage Disease
Some pretty good evidence suggests that chemotherapy that works in advanced disease probably works even better in early-stage disease,” said Fadlo R. Khuri, MD, Chair, Department of Hematology and Medical Oncology at Winship Cancer Institute in Atlanta, in summarizing results from trials of...
Lung Cancer Expert Offers Recommendations for Treating Toxicities Associated With Targeted Therapies
Clearly life as a thoracic oncologist has changed. Our paradigm for giving one-size-fits-all chemotherapy seems a bit dated, as we now are learning that there are multiple targets that we can treat effectively with the right drugs,” Jyoti D. Patel, MD, Associate Professor of Medicine at...
CMS Issues Preliminary Decision to Cover Annual Lung Cancer Screening
In a long-awaited decision, the Centers for Medicare & Medicaid Services (CMS) has issued a preliminary proposal to cover annual lung cancer screening with low-dose computed tomography for appropriate beneficiaries following counseling and a shared–decision-making visit with a qualified...
Transplants for AML in First Remission: A Great Leap Forward, Sideways, or Backward?
“All great truths begin as blasphemies.” —George Bernard Shaw (Annajanksa, 1918) Until about 15 years ago, persons with acute myelogenous leukemia (AML) were considered candidates to receive a blood cell or bone marrow allotransplant in first remission only if they had had an HLA-identical...
PD-1 Blockade Moves Into Hematology
The promise of the programmed death receptor-1 (PD-1) inhibitors seen in solid tumors, especially melanoma, may hold true for at least one hematologic malignancy, according to studies presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition. At a press briefing, data ...
ASCO Announces Major Steps in Development of CancerLinQ™
The American Society of Clinical Oncology (ASCO) announced that its wholly owned subsidiary, CancerLinQ LLC, will use the SAP HANA® platform in the development of ASCO’s CancerLinQ™. CancerLinQ is a groundbreaking health information technology platform that will harness Big Data to deliver...
Better Studies Needed to Dispel Confusion Over When to Refer a Patient to Hospice
I read the article on “Private Payer and Academic Center Data Capture Inappropriate Use of End-of Life Care” (The ASCO Post, December 15, 2014, page 11). The data highlight Dr. Deborah Schrag’s notion that there is “ample evidence of overuse of intensive care at the end of life.” However, there is...
Mammographic Density Is Highly Heritable, Possibly Explaining the Familial Aggregation of Breast Cancer
Using a fully automated method to ascertain volumetric mammographic density, a study conducted by the Karolinska Mammography (KARMA) project for risk prediction of breast cancer in Sweden confirmed the high heritability of mammographic density, although estimates were weaker for absolute than for...
About 25% of Patients Who Undergo Breast-Conservation Surgery for Stage 0 to II Carcinoma Have Subsequent Surgery
“Approximately one-fourth of all patients who undergo initial breast-conservation surgery for breast cancer will have a subsequent operative intervention,” concluded a study published online by JAMA Surgery. “The rate of repeat surgeries varies by patient, tumor, and facility factors,” reported Lee ...
Ten Best-Practice Measures Improve Quality of Care During Perioperative Period for Patients With Glioma
Ten best-practice measures identified by a multidisciplinary team at the Norris Cotton Cancer Center (NCCC) at the Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire, were used to improve the care provided to patients with glioma during the perioperative period. “Using a plan-do-study-act ...
Patients With Chronic Lymphocytic Leukemia Who Progress After Front-line Treatment May Be Candidates for Novel Noncytotoxic Therapies
Although patients who relapse within 3 years of front-line fludarabine, cyclophosphamide, and rituximab (Rituxan; FCR) therapy have poor survival when treated with conventional salvage regimens, these patients may be candidates for novel noncytotoxic therapies, according to an analysis of extended...
AJCC Cancer Staging System Is Most Accurate Measuring Response to Chemoradiation in Locally Advanced Rectal Cancer
When classifying response to chemoradiation among patients with locally advanced rectal cancer, the American Joint Committee on Cancer (AJCC) Cancer Staging Manual (7th edition) system “is most accurate and should be adopted as the standard,” Attaphorn Trakarnsanga, MD, and colleagues at Memorial...
Citing Guidelines May Reassure Patients
Whether deviations from treatment guidelines are warranted to provide optimal personalized care, or should be financially penalized for straying from evidence-based care, has raised questions among insurers and physicians and caused a stir in the press. In general, however, patients with cancer are ...
Physicians Need to Maintain Flexibility to Deviate From Treatment Guidelines Without Financial Penalties
With the provocative headline, “How Medical Care Is Being Corrupted,” an op-ed piece in The New York Times argued that “financial forces largely hidden from the public are beginning to corrupt care and undermine the bond of trust between doctors and patients.”1 The article warned that insurers,...
Electro-Gynecology, Philadelphia, 1883
Through the Lens of Oncology History A Century of Progress The text and photographs on these pages represent the establishment of oncology as a viable medical specialty during the mid-1800s. The images and captions are excerpted from a four-volume series of books titled Oncology Tumors &...
